

Patients' and consumers' organisation funding sources

NAME OF ORGANISATION: Myeloma Patients Europe (MPE)

YEAR: 2021

MPE Industry ¹ related income ²		
Name of company/ funder	Amount of income	% of overall organisation's income
Amgen	98.358 €	8,43%
Bristol Myers Squibb	120.000 €	10,28%
Gilead	19.400 €	1,66%
GSK	92.263 €	7,90%
Janssen	154.690 €	13,25%
Karyopharm	50.000 €	4,28%

¹ Industry is defined as commercial manufacturers of healthcare products and services, including distributors and wholesalers, etc.

² This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.

Novartis	35.842 €	3,07%
Pfizer	48.960 €	4,19%
Roche	65.000 €	5,57%
Sanofi	70.988 €	6,08%
Sobi	1.430 €	0,12%
Takeda	268.895 €	23,03%
UCB	1.200 €	0,10%
Subtotal:	1.027.026 €	87,97 %

MPE Non-industry related income – Public Funding		
Source of funding ³	Amount of income	% of overall organisation's income
H2020 CARAMBA	21.166 €	1,81%
H2020 MMPREDICT	4.484 €	0,38%
IMI HARMONY	19.881 €	1,70%
IMI SISAQoL	70.875 €	6,07%
Subtotal:	116.406 €	9,97%

³ E.g. membership fees, donations.

MPE Non-industry related income		
CDDF	1.000 €	0,09%
EUPATI	1.483 €	0,13%
REFUND - Flight bookings	2.283 €	0,20%
REFUND - Non Industry (various)	1.897 €	0,16%
REFUND - Social security contribution	17.330 €	1,48%
Subtotal:	23.993 €	2,06 %
TOTAL⁴:	1.167.425 €	100,00 %

Information required to be included on organisation's website	Please include links below:
<ul style="list-style-type: none"> Funding sources: 	https://www.mpeurope.org/about-mpe/funding-sources/
<ul style="list-style-type: none"> Overall proportion of industry and non-industry: 	Industry: 87,97 %; Non-Industry incl. Public Funding: 12,03 %
<ul style="list-style-type: none"> Percentage of the highest contribution from a single company: 	23,03 % of overall organizations income

⁴ In case the total figures in this table do not match those in the financial statement, please provide justification (attached here or as an email).

Comments/explanatory notes:

When completing the form you may refer to the guidance document here (in particular point 4, pages 8-9):

http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2015/05/WC500187018.pdf